HIV mutation literature information.


  HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.
 PMID: 28114955       2017       AIDS research and therapy
Table: K238T


  Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
 PMID: 27120449       2016       PloS one
Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,


  The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.
 PMID: 26930645       2016       PloS one
Method: M46I, I54V, V82A, M46IN88S, G48VI54V, M46IV82TI84V, and G48VI54VV82A mutations were introduced into the PR coding region, and K103N, Y181C, K103NY181C, K101Q, K101QY181C, K101QH221Y,  PMID: 26602836       2016       AIDS research and human retroviruses
Abstract: Level of DRMs was low (3.77%) versus moderate (7.55%), respectively, following the WHO list (T69D, K103N) versus Stanford HIVdb (T69D, A98G, K103N, K238T), respectively.


  HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
 PMID: 26558396       2015       PloS one
Table: K238T


  Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
 PMID: 26107265       2015       PloS one
Result: Sixteen out of 23 (70%) had NNRTI mutations (Y181C/I/D: 10; K103N: 6; V106A/I: 3; Y188C/L: 2; K101Q/E: 2; M230L: 1; P225H: 1; A98G: 1; V108I: 1; F227L: 1; K238T: 1), and 10 had >1 NNRTI mutation.
Table: K238T


  Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
 PMID: 25849352       2015       PLoS medicine
Result: Nevirapine and efavirenz resistance were predicted in about 1% and 0.5% of virus samples without NNRTI SDRMs as a result of several minimally polymorphic (e.g., A98G, V108I, and V179D) and rare nonpolymorphic (e.g., E138K, G190Q, F227C, and K238T) NNRTI-resistance mutations.


  Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland.
 PMID: 24746180       2014       Journal of the International AIDS Society
Result: Of note, in the analysed sample, in six patients (2.5%) key NNRTI mutations not associated with RPV were noted, with K103N being the most common (five cases, 2.1%), including one case with a triple K101E/K103N/G190A mutation and one with K103N/P225H/K238T.
Discussion: It should be observed that prevalence of the RPV key drug resistance mutations in our sample is higher than that of the K103N mutation, observed in 2.1% of cases, while etravirine resistance-associated mutations were rare (one sequence each with K238T and Y318F).


  HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.
 PMID: 24456757       2014       AIDS research and therapy
Table: K238T


  [Resistance evolutionary pathway analysis of HIV-1 CRF_07BC reverse transcriptase].
 PMID: 24969455       2014       Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Abstract: While for B subtype, the major resistance mutations include M184V, K103N,Y181C, T69N,G190A, K238T,Y188H and P225H.



Browser Board

 Co-occurred Entities




   Filtrator